Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity
Michael Linecker, Bergthor Björnsson, Gregor A Stavrou, Karl J Oldhafer, Georg Lurje, Ulf Neumann, René Adam, Francois-René Pruvot, Stefan A Topp, Jun Li, Ivan Capobianco, Silvio Nadalin, Marcel Autran Machado, Sergey Voskanyan, Deniz Balci, Roberto Hernandez-Alejandro, Fernando A Alvarez, Eduardo De Santibañes, Ricardo Robles-Campos, Massimo Malagó, Michelle L de Oliveira, Mickael Lesurtel, Pierre-Alain Clavien, Henrik Petrowsky, Michael Linecker, Bergthor Björnsson, Gregor A Stavrou, Karl J Oldhafer, Georg Lurje, Ulf Neumann, René Adam, Francois-René Pruvot, Stefan A Topp, Jun Li, Ivan Capobianco, Silvio Nadalin, Marcel Autran Machado, Sergey Voskanyan, Deniz Balci, Roberto Hernandez-Alejandro, Fernando A Alvarez, Eduardo De Santibañes, Ricardo Robles-Campos, Massimo Malagó, Michelle L de Oliveira, Mickael Lesurtel, Pierre-Alain Clavien, Henrik Petrowsky
Abstract
Objective: To longitudinally assess whether risk adjustment in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) occurred over time and is associated with postoperative outcome.
Background: ALPPS is a novel 2-stage hepatectomy enabling resection of extensive hepatic tumors. ALPPS has been criticized for its high mortality, which is reported beyond accepted standards in liver surgery. Therefore, adjustments in patient selection and technique have been performed but have not yet been studied over time in relation to outcome.
Methods: ALPPS centers of the International ALPPS Registry having performed ≥10 cases over a period of ≥3 years were assessed for 90-day mortality and major interstage complications (≥3b) of the longitudinal study period from 2009 to 2015. The predicted prestage 1 and 2 mortality risks were calculated for each patient. In addition, questionnaires were sent to all centers exploring center-specific risk adjustment strategies.
Results: Among 437 patients from 16 centers, a shift in indications toward colorectal liver metastases from 53% to 77% and a reverse trend in biliary tumors from 24% to 9% were observed. Over time, 90-day mortality decreased from initially 17% to 4% in 2015 (P = 0.002). Similarly, major interstage complications decreased from 10% to 3% (P = 0.011). The reduction of 90-day mortality was independently associated with a risk adjustment in patient selection (P < 0.001; OR: 1.62; 95% CI: 1.36-1.93) and using less invasive techniques in stage-1 surgery (P = 0.019; OR: 0.39; 95% CI: 0.18-0.86). A survey indicated risk adjustment of patient selection in all centers and ALPPS technique in the majority (80%) of centers.
Conclusions: Risk adjustment of patient selection and technique in ALPPS resulted in a continuous drop of early mortality and major postoperative morbidity, which has meanwhile reached standard outcome measures accepted for major liver surgery.
Source: PubMed
即将进行的临床试验
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied Practice尚未招聘
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLC尚未招聘
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata Verona尚未招聘
-
University of Wisconsin, MadisonAlkermes, Inc.尚未招聘
-
Virginia Commonwealth University尚未招聘
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount Sinai尚未招聘氯胺酮 | 功能磁共振成像 | 抑郁症 - 重度抑郁症 | 经颅磁刺激 | 难治性抑郁症 (TRD)美国
-
Weill Medical College of Cornell UniversityBD2 LLC尚未招聘功能磁共振成像 | 双相情感障碍 (BD) | 经颅磁刺激 | 双极 1 抑郁症美国
-
Yale UniversityNational Institute of Mental Health (NIMH)尚未招聘
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridge招聘中嗜铬细胞瘤 | 嗜铬细胞瘤/副神经节瘤 | 嗜铬细胞瘤,转移性 | 嗜铬细胞瘤恶性 | 嗜铬细胞瘤和paraganglioma(PPGL)英国
-
Carl Zeiss Meditec-Dublin CoCe招聘中视网膜前膜 | 视网膜疾病 | 干性年龄相关性黄斑变性 | 玻璃体视网膜异常 | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium (RPE) Atrophy美国
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical University招聘中